The price-to-earnings ratio for Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is above average at 19.36x. The 36-month beta value for REGN is also noteworthy at 0.10. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 7 rating it as “overweight,” 12 rating it as “hold,” and 1 rating it as “sell.”
The public float for REGN is 105.96M, and at present, short sellers hold a 1.75% of that float. The average trading volume of REGN on November 15, 2024 was 645.84K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
REGN) stock’s latest price update
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has experienced a decline in its stock price by -2.71 compared to its previous closing price of 804.33. However, the company has seen a fall of -5.09% in its stock price over the last five trading days. fool.com reported 2024-11-14 that Their recent issues are nothing to fret over for investors focused on the long game.
REGN’s Market Performance
Regeneron Pharmaceuticals, Inc (REGN) has seen a -5.09% fall in stock performance for the week, with a -22.37% decline in the past month and a -33.65% plunge in the past quarter. The volatility ratio for the week is 1.95%, and the volatility levels for the past 30 days are at 2.62% for REGN.. The simple moving average for the past 20 days is -10.81% for REGN’s stock, with a -22.33% simple moving average for the past 200 days.
Analysts’ Opinion of REGN
Leerink Partners, on the other hand, stated in their research note that they expect to see REGN reach a price target of $1077, previously predicting the price at $1175. The rating they have provided for REGN stocks is “Market Perform” according to the report published on September 24th, 2024.
Bernstein gave a rating of “Outperform” to REGN, setting the target price at $1125 in the report published on March 12th of the current year.
REGN Trading at -21.17% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.39% of loss for the given period.
Volatility was left at 2.62%, however, over the last 30 days, the volatility rate increased by 1.95%, as shares sank -21.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.99% lower at present.
During the last 5 trading sessions, REGN fell by -5.09%, which changed the moving average for the period of 200-days by -17.00% in comparison to the 20-day moving average, which settled at $877.34. In addition, Regeneron Pharmaceuticals, Inc saw -10.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.84 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.34. The total capital return value is set at 0.12. Equity return is now at value 17.17, with 13.37 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 2.14. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 63.56.
Currently, EBITDA for the company is 4.65 billion with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 6.16. The receivables turnover for the company is 2.27for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.28.
Conclusion
In summary, Regeneron Pharmaceuticals, Inc (REGN) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
